Prognostic role of DOK family adapters in acute myeloid leukemia

Acute myeloid leukemia (AML) is a genetically and clinically heterogeneous disease. Gene mutational and expressional profile can aid the identification of different prognostic subgroups. Downstream of tyrosine kinase ( DOK ) proteins are a multigenic family of adaptors; some of them are key negative...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer gene therapy 2019-09, Vol.26 (9-10), p.305-312
Hauptverfasser:	Zhang, Lin, Li, Ran, Hu, Kai, Dai, Yifeng, Pang, Yifan, Jiao, Yang, Liu, Yan, Cui, Longzhen, Shi, Jinlong, Cheng, Zhiheng, Fu, Lin
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1990/283 692/53 Acute myeloid leukemia Adaptor proteins Adaptor Proteins, Signal Transducing - genetics Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers, Tumor Biomedical and Life Sciences Biomedicine Chemotherapy Databases, Genetic Dok1 protein Female Gene Expression Gene Expression Regulation, Leukemic Gene Therapy Genomes Hematopoietic stem cells Humans Kaplan-Meier Estimate Leukemia Leukemia, Myeloid, Acute - diagnosis Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - mortality Male Middle Aged Multigene Family Multivariate analysis Mutation Myeloid leukemia Prognosis Protein-tyrosine kinase Risk factors Stem cell transplantation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Acute myeloid leukemia (AML) is a genetically and clinically heterogeneous disease. Gene mutational and expressional profile can aid the identification of different prognostic subgroups. Downstream of tyrosine kinase ( DOK ) proteins are a multigenic family of adaptors; some of them are key negative regulators of immune cell signaling. However, the expression and clinical implication of DOK family in AML has rarely been investigated. A total of 155 AML patients with DOK family ( DOK1-7 ) expression data from The Cancer Genome Atlas database were enrolled in the study. In patients who only received chemotherapy, those with high expressions of DOK4 or DOK5 had significantly shorter EFS and OS than patients with low expressions (all P
ISSN:	0929-1903 1476-5500
DOI:	10.1038/s41417-018-0052-z